Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02134340
Recruitment Status : Completed
First Posted : May 9, 2014
Last Update Posted : October 18, 2016
Sponsor:
Information provided by (Responsible Party):
Centre for Probe Development and Commercialization

Brief Summary:
The purpose of the study is to evaluate the safety and biodistribution of [I-124]-CPD-1028 Injection in cancer patients with solid tumours.

Condition or disease Intervention/treatment Phase
Cancer Drug: [I-124]-CPD-1028 Injection Biological: CPD-1061 Phase 1

Detailed Description:
Up to 18 adult participants will be enrolled in this Phase 1a study to evaluate the safety and biodistribution of [I-124]-CPD-1028 Injection in patients with Insulin-like Growth Factor-1R (IGF-1R) upregulated solid tumours. All eligible subjects who have given written informed consent and qualify based on the study's inclusion/exclusion criteria will be enrolled in the study. Each enrolled subject will take part in six visits consisting of a screening visit, an Investigational Product administration visit, 3 assessment visits involving 2-3 Positron Emission Tomography/Computed Tomography (PET/CT) scans, and a follow-up safety telephone call. At Visit 2, subjects will start a course of treatment to protect the thyroid from radioactivity and may receive a pre-targeting dose of an additional investigational agent, CPD-1061.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 1a, Multi-centre, Open-label, Non-randomized Study to Assess the Safety, Biodistribution and Tumour Uptake of [I-124]-CPD-1028 Injection
Study Start Date : June 2014
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: [I-124]-CPD-1028 PET/CT

Administration of [I-124]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions.

A pre-targeting dose of CPD-1061 may be given prior to injection of [I-124]-CPD-1028.

Drug: [I-124]-CPD-1028 Injection
A single intravenous dose of [I-124]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.

Biological: CPD-1061
[Optional] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of [I-124]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.




Primary Outcome Measures :
  1. Evaluate safety of [I-124]-CPD-1028 Injection [ Time Frame: Up to 30 days ]
    The safety of [I-124]-CPD-1028 Injection will be assessed for up to 30 days post injection by measuring the occurrence of adverse events and changes from baseline in physical examination, clinical laboratory parameters, electrocardiogram recordings, and vital signs (blood pressure, heart rate, body temperature, respiratory rate and oxygen saturation).

  2. Obtain preliminary biodistribution data for [I-124]-CPD-1028 [ Time Frame: Up to 18 days ]
    Biodistribution data will be assessed by quantitative analysis of imaging scans taken 2-3 days and 5-7 days post injection by (1) measuring tumour uptake and background tissue levels in selected regions of interest on whole body images and (2) determining if suitable quantitative imaging metrics can be identified.


Secondary Outcome Measures :
  1. Measure blood and plasma clearance of [I-124]-CPD-1028 and levels of free [I-124]-Iodide [ Time Frame: Up to 18 days ]
    Blood and plasma clearance of [I-124]-CPD-1028 and levels of free [I-124]-iodide will be assessed by analysis of blood and plasma samples taken up to 18 days post-injection.

  2. Compare [I-124]-CPD-1028 uptake in tumours to IGF-1R expression [ Time Frame: Up to 18 days ]
    [I-124]-CPD-1028 PET/CT images taken up to 18 days post-injection will be compared to immunohistochemistry staining scores of IGF-1R on previously obtained tumour samples.

  3. Compare [I-124]-CPD-1028 PET/CT images to other imaging modalities [ Time Frame: Up to 18 days ]
    [I-124]-CPD-1028 PET/CT images taken up to 18 days post-injection will be visually (qualitatively) compared to previously obtained CT and/or MRI images.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥18 years old with life expectancy > 12 weeks with confirmed metastatic or unresectable malignancy
  2. Patients must have progressed after at least first-line chemotherapy and have an Eastern Cooperative Oncology Group (ECOG) status of 0, 1 or 2.
  3. All patients must have archival tumour samples available and must have verification of IGF-1R expression.
  4. Patients must have adequate organ and marrow function, vital signs and ECG.
  5. Females of childbearing potential must not be pregnant and both males and females must use adequate forms of contraception.
  6. Signed informed consent form
  7. Subject must be compliant and have a high probability of completing the study.

Exclusion Criteria:

  1. Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from previous treatment.
  2. Patients who have received a therapeutic radiopharmaceutical in the past year or who are currently receiving any other investigational agents.
  3. Previous treatment with IGF-1R inhibitors.
  4. Patients who are currently taking antithyroid medications and lithium or potassium sparing diuretics.
  5. Subjects with known or suspected allergies or contraindications to the investigational agents and iodine
  6. Subjects with uncontrolled intercurrent illness
  7. Female subjects who are pregnant, planning to become pregnant or are lactating and/or breast-feeding.
  8. Patients with diabetes requiring therapy unless controlled through diet or metformin.
  9. Subjects who are undergoing monitoring of occupational ionising radiation exposure.
  10. Subjects with hypothyroidism requiring thyroid supplementation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02134340


Locations
Layout table for location information
Canada, Ontario
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada, L8N 3Z5
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2
Sunnybrook Health Science Centre - Odette Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Centre for Probe Development and Commercialization
Investigators
Layout table for investigator information
Study Director: Eric Burak, PhD Centre for Probe Development and Commercialization
Layout table for additonal information
Responsible Party: Centre for Probe Development and Commercialization
ClinicalTrials.gov Identifier: NCT02134340    
Other Study ID Numbers: CPD1028-01
First Posted: May 9, 2014    Key Record Dates
Last Update Posted: October 18, 2016
Last Verified: April 2016
Keywords provided by Centre for Probe Development and Commercialization:
IGF1R